Basic Midodrine Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In United Kingdom: Sukkarto, Bolamyn, Metabet
• ATC Code: A10BA02
• Forms & Dosages: Oral tablets (250mg, 500mg, 850mg, 1000mg immediate and sustained release); oral solution (500mg/5ml); sachets (rare)
• Manufacturers In United Kingdom: Merck (Glucophage), Teva, Sandoz, Actavis, Sun Pharma, Dr. Reddy’s, Mylan, Zentiva
• Registration Status In United Kingdom: Approved and registered; prescription-only in national registries
• OTC / Rx Classification: Prescription-only (Rx)

Major 2022–2025 Studies

Main Outcomes

Worried whether midodrine really helps people who keep feeling dizzy or fainting when they stand up?

Recent placebo-controlled randomised studies and meta-analyses from 2018 to 2024 consistently show meaningful clinical benefit for patients with neurogenic orthostatic hypotension.

Standing systolic blood pressure typically rose by about 15–25 mmHg within one to two hours after dosing in large trials.

Patients reported fewer dizziness days and lower scores on validated symptom instruments after starting midodrine at doses titrated to effect.

The pressor response proved dose-dependent and was most consistent with 5 mg to 10 mg given two to three times daily.

Trials usually measured pragmatic endpoints such as orthostatic tolerance and symptom days rather than long‑term cardiovascular outcomes.

This means clinicians have good short‑term efficacy data but still seek longer safety and hard‑outcome studies.

Safety Observations

Concerned about side effects and who should avoid midodrine?

The principal safety signal across studies is supine hypertension, observed in roughly 10–25% of participants depending on dose and monitoring intensity.

Other treatment‑related effects included piloerection, paraesthesia and urinary hesitancy, which are usually reversible after dose reduction or stopping treatment.

Serious ischaemic complications are uncommon but possible in patients with critical coronary or peripheral arterial disease, and trials underline the need for careful baseline screening.

Overall, the safety profile is consistent across trials and matches long‑standing clinical experience.

Layman’s Explanation

Are you short of breath on standing or dizzy when you get up from a chair?

Midodrine is a short‑acting tablet that helps prevent the drop in blood pressure that causes light‑headedness and fainting when standing.

It works by making small blood vessels tighten a bit, so blood stays in the right places when you stand up.

Most people notice benefit within an hour of a dose, and the effect lasts long enough for daytime activities when dosed two or three times daily.

Scientific Breakdown

Receptor Targets

Wondering how midodrine causes that tightening of blood vessels?

Midodrine itself is a prodrug that is rapidly converted to the active compound desglymidodrine.

Desglymidodrine is a selective α1‑adrenergic receptor agonist that stimulates peripheral arteriolar and venous α1 receptors.

That receptor activation increases vasoconstriction, raises systemic vascular resistance and improves venous return when standing.

Pharmacokinetics

Want to know how quickly it works and how the body clears it?

Oral midodrine is absorbed quickly and the active metabolite peaks at about one hour post‑dose.

The half‑life of desglymidodrine supports dosing two to three times during waking hours for daytime symptom control.

Renal excretion is the main elimination route for the active metabolite, so impaired kidney function increases exposure and requires dose caution.

Because activity is peripheral, central sympathetic stimulation is minimal and the main clinical downside remains supine hypertension when dosing overlaps sleep.

United Kingdom Approvals

Does the NHS prescribe midodrine for orthostatic symptoms?

Midodrine is indicated in most national formularies for symptomatic orthostatic hypotension when non‑pharmacological measures and first‑line treatments such as fludrocortisone are inadequate.

In the UK midodrine is a prescription medicine and clinicians typically prescribe branded generics alongside unbranded tablets.

Access may be governed by local NHS formularies or specialist clinic pathways for patients with Parkinson’s disease, multiple system atrophy or diabetic autonomic neuropathy.

Notable Off‑Label Trends

Could midodrine help other types of low blood pressure?

Off‑label use includes refractory intradialytic hypotension, persistent vasodilation‑related syncope and hypotension following spinal cord injury.

Small case series and specialist centres sometimes use midodrine short‑term in the peri‑operative setting for orthostatic intolerance.

Regulatory caution and the risk of supine hypertension generally limit broad off‑label adoption, and clinicians individualise choice based on comorbidities and monitoring capacity.

General Dosing

What dose should a patient expect when starting midodrine?

Typical adult dosing ranges from 2.5 mg to 10 mg per dose, administered two to three times daily during waking hours.

Most clinicians start low—often 2.5 mg once or twice daily—and titrate every three to seven days to clinical effect.

Common maintenance regimens centre on 5 mg three times daily, with a usual upper limit of 10 mg three times daily though many prescribers cap lower.

Condition‑Specific Dosing

Titration & Timing

How should doses be adjusted for different situations?

For neurogenic orthostatic hypotension, maintenance doses of 5–10 mg three times daily are commonly required for symptom control.

For intradialytic hypotension, a single dose timed just before dialysis is used in many protocols to raise perfusion during the session.

Always give the last daytime dose at least three to four hours before bedtime to reduce the risk of supine hypertension.

In renal impairment reduce the dose or extend dosing intervals because the active metabolite accumulates with decreased clearance.

Paediatric use is rare and requires specialist advice; monitor standing and supine blood pressure during titration and use symptom improvement to guide maintenance dosing.

Contraindications

Who must not take midodrine?

Absolute contraindications include persistent supine hypertension and known hypersensitivity to the drug.

Patients with pheochromocytoma should not receive midodrine because of the risk of severe hypertension.

Use with caution in severe cardiac disease, peripheral vascular disease, urinary retention and severe renal impairment, and seek specialist advice in pregnancy or breastfeeding.

Adverse Effects

What side effects should patients expect and how are they handled?

Supine hypertension is the most important adverse effect and is the commonest reason for dose reduction or stopping treatment.

Other frequent reactions include scalp tingling and piloerection, paraesthesia, pruritus, urinary hesitancy and sensations of chills.

Less common but serious events include ischaemic problems if vasoconstriction unmasks critical coronary or peripheral arterial disease, so review cardiac history before prescribing.

Safety protocols include baseline supine and standing blood pressure measurement, renal function checks if indicated and clear patient counselling on symptoms that require urgent review.

Food Interactions

Do meals change how midodrine works?

Absorption is not strongly affected by food, but taking doses with or just after food can reduce gastric discomfort for some patients.

Timing doses relative to meals does not generally change the pressor effect, so patients may follow practical advice to take midodrine with food to improve tolerability.

Drug Combinations To Avoid

Which medicines should be avoided or monitored when taking midodrine?

Combining midodrine with other pressor agents such as intravenous catecholamines, phenylephrine or potent sympathomimetics increases the risk of marked hypertension.

MAO inhibitors and some sympathomimetics can potentiate pressor responses and warrant close review or avoidance.

Antihypertensives may be less effective when midodrine is active, so review background therapy including diuretics and ACE inhibitors when starting treatment.

Medications that impair urinary outflow, for example anticholinergics, may worsen urinary retention and should be used with caution.

Always check renal clearance interactions when patients are taking drugs that reduce renal elimination, since the active metabolite is renally excreted.

Survey Data

Do patients say midodrine helps in real life?

Clinical registries and patient‑reported outcome instruments indicate many patients experience clinically meaningful improvement in orthostatic symptoms and fewer syncope days.

Real‑world data suggest around 50–70% of users report symptomatic relief sufficient to improve daily function and reduce falls in observational series.

Discontinuation most commonly follows supine hypertension, nocturnal discomfort or urinary side effects rather than lack of efficacy.

Forum Trends

What do patient forums and support groups say about living with midodrine?

Patients often report regained confidence standing, fewer care needs and improved ability to leave the house once effective dosing is found.

Common complaints mirror trial data: night‑time hypertension, scalp tingling and the inconvenience of multiple daily dosing.

Practical coping tips shared online include strict timing of the last dose, using a head‑elevated sleeping position and combining medication with compression garments and slow rising techniques.

UK Supply Chains

How is midodrine supplied in the United Kingdom?

Midodrine is dispensed as a prescription‑only medicine through community and hospital pharmacies across the UK.

Both branded generics and unbranded midodrine tablets are available, and wholesalers supply community pharmacies subject to stock and demand for this relatively specialised therapy.

Local NHS formularies and trust policies can affect which brands and pack sizes are stocked by particular hospitals or clinics.

Price Drivers & Generics

How much should patients expect to pay and why does price vary?

Price depends on manufacturer, pack size and tablet strength, with generic competition generally keeping costs moderate compared with newer specialised agents.

Because the treated population for neurogenic orthostatic hypotension is small, some suppliers limit production runs and that can occasionally affect availability and price.

For context, widely variable branding and packaging practices seen with oral drugs such as metformin demonstrate how the same INN may be sold under multiple labels and pack sizes across regions.

In our online pharmacy, midodrine is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparison Table

Which alternatives relieve orthostatic symptoms and how do they compare?

• Midodrine — rapid peripheral pressor, good for daytime symptoms, risk of supine hypertension; requires two to three times daily dosing.
• Fludrocortisone — expands plasma volume over days to weeks, useful for longer‑term volume support but carries hypokalaemia and oedema risk.
• Droxidopa — precursor to norepinephrine that increases central and peripheral norepinephrine levels, less widely available in the UK and more costly.
• Non‑pharmacological measures — compression garments, increased salt and fluids, physical counter‑pressure maneuvers are low risk and often first‑line adjuncts.

Pros And Cons

How should choice be individualised?

Midodrine scores well for fast onset and titratability which is valuable for daytime symptomatic control.

Fludrocortisone works by volume expansion and may suit people who can tolerate sodium retention and monitoring for low potassium.

Droxidopa can be effective but is less accessible and more expensive in the UK market.

Combination therapy, commonly midodrine with fludrocortisone, is an option when single agents fail, and requires careful multidisciplinary monitoring.

Licensing & Prescription Status

Is reporting and monitoring required for midodrine in routine practice?

Midodrine is a prescription‑only medicine in the UK with branded and generic formulations authorised for symptomatic orthostatic hypotension.

Access in some areas is governed by local NHS formularies and specialist service pathways to ensure suitable patient selection and monitoring.

Pharmacovigilance Requirements

How should clinicians report adverse reactions?

Prescribers and pharmacists should report suspected adverse reactions, particularly supine hypertension and ischaemic events, to the Yellow Card scheme.

Because most trials prioritise short‑term symptom endpoints, ongoing post‑marketing surveillance and registry data are important to capture longer‑term safety and rare events.

Provide patients with written information on side effects and clear instructions on home supine and standing blood pressure checks when indicated.

Quick Answers For Clinicians & Patients

What are the most practical questions people ask about midodrine?

How fast does midodrine work?

The active metabolite peaks at around one hour and symptomatic benefit is often seen within that timeframe.

When should the last dose be taken?

Give the last dose at least three to four hours before bedtime to reduce the chance of supine hypertension.

Is it safe in renal impairment?

Use caution because the active metabolite is renally excreted; reduce dose or extend intervals and monitor renal function and blood pressure.

Can it cause headaches and urinary problems?

Yes; piloerection, paraesthesia, urinary hesitancy and headaches are commonly reported and usually manageable with dose adjustment.

What about driving and safety?

If orthostatic symptoms are uncontrolled, advise against driving until stability is demonstrated and documented in the clinical record.

What to do in pregnancy or breastfeeding?

Specialist advice is required and treatment should be considered only after a careful risk/benefit discussion.

Suggested Figures & Charts

What visuals help patients and clinicians understand midodrine use?

Include a dosing timeline graphic that shows a typical three‑times‑daily schedule and highlights the need to avoid taking doses within three to four hours of sleep.

Show a supine versus standing blood pressure chart with thresholds prompting dose change or urgent review.

Provide a symptom diary template capturing syncope or light‑headedness days, triggers and dose timing to aid titration.

Patient Handout Elements

What should be on the printed advice given at dispensing?

Use plain UK English and large font for older adults, and include icons for “take with food”, “do not take at bedtime”, “measure supine and standing BP” and emergency signs such as chest pain or severe headache.

Mention brand name examples on the label and remind patients to carry prescription details when travelling.

Pharmacy Handling

How should pharmacies store and dispense midodrine tablets?

Store tablets at controlled room temperature and protect from moisture in the original blister pack when possible.

Avoid prolonged exposure to heat during transport and label packs clearly with expiry and patient instructions.

Patient Storage Advice

What should patients know about keeping medication at home?

Advise storage at room temperature away from direct sunlight and moisture and to keep the medication in the original packaging out of reach of children.

Recommend carrying a copy of the prescription when travelling and keeping tablets in hand luggage to avoid extremes of temperature in hold luggage.

Monitoring Checklist

What baseline checks and follow‑up are essential when prescribing midodrine?

Record baseline supine and standing blood pressure (lying then standing at one and three minutes), document symptom burden and review cardiac history and current medications.

Check renal function if there is any concern about impaired clearance and schedule BP checks during titration and after dose changes.

Prescribing Best Practice

What practical prescribing steps reduce risk and improve outcomes?

Start at the lowest effective dose such as 2.5 mg and titrate to symptom relief while avoiding late evening dosing.

Provide written informed advice about supine hypertension and arrange multidisciplinary referral for refractory cases.

Encourage concurrent non‑pharmacological measures such as increased salt and fluids, compression garments and physical counter‑pressure techniques.

Report adverse events through the Yellow Card scheme and document patient education at dispensing.

Delivery Across United Kingdom